Home » Stocks » IONS

Ionis Pharmaceuticals, Inc. (IONS)

Stock Price: $51.22 USD 0.25 (0.49%)
Updated December 4, 4:00 PM EST - Market closed

IONS Stock Price Chart

Key Info

Market Cap 7.16B
Revenue (ttm) 932.66M
Net Income (ttm) 73.40M
Shares Out 139.71M
EPS (ttm) 0.52
PE Ratio 98.88
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $51.22
Previous Close $50.97
Change ($) 0.25
Change (%) 0.49%
Day's Open 51.23
Day's Range 50.75 - 51.37
Day's Volume 566,112
52-Week Range 41.60 - 65.27

IONS Stock News

Zacks Investment Research - 16 hours ago

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 2 days ago

CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtual f...

PRNewsWire - 3 days ago

CARLSBAD, Calif., Dec. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients wi...

PRNewsWire - 3 days ago

CARLSBAD, Calif., Dec. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live investor day webcast on Monday, December 7th at 11:00 a.m. Ea...

PRNewsWire - 4 days ago

CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical tria...

PRNewsWire - 1 week ago

CARLSBAD, Calif., Nov. 23, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigationa...

PRNewsWire - 3 weeks ago

CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that new data for ION449, an investigational antisense medicine designed to reduce pl...

PRNewsWire - 3 weeks ago

CARLSBAD, Calif., Nov. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the upcoming presentations of clinical and non-clinical data for several of its inve...

PRNewsWire - 3 weeks ago

CARLSBAD, Calif., Nov. 10, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that accomplished Ionis scientists will highlight the company's pioneering advancemen...

PRNewsWire - 3 weeks ago

CARLSBAD, Calif., Nov. 9, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview...

Business Wire - 3 weeks ago

LONDON--(BUSINESS WIRE)--Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Scottish Medicines Consortium (SMC) has enabled a...

Business Wire - 4 weeks ago

BOSTON & CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, today recognize the 3rd annual Familial Chylomicronemia Sy...

Zacks Investment Research - 4 weeks ago

Ionis (IONS) posts wider-than-expected Q3 loss. Sales miss estimates.

Seeking Alpha - 1 month ago

Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q3 2020 Results - Earnings Call Transcript

The Motley Fool - 1 month ago

The main problem: a lackluster performance for Spinraza.

Zacks Investment Research - 1 month ago

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -144.44% and -15.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead ...

Benzinga - 1 month ago

  Shares of Ionis Pharmaceuticals (NASDAQ:IONS) moved higher by 1.6% in pre-market trading after the company reported Q3 results.

PRNewsWire - 1 month ago

CARLSBAD, Calif., Nov. 4, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the third quarter of 2020 and recent business highlights. "We...

PRNewsWire - 1 month ago

CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. ...

Other stocks mentioned: PFE
PRNewsWire - 1 month ago

BOSTON and CARLSBAD, Calif., Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, received the Prix Galien USA Award fo...

Zacks Investment Research - 1 month ago

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 1 month ago

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

Other stocks mentioned: CBPO, GLPG, HRTX, ILMN, RGNX, LGND
PRNewsWire - 1 month ago

CARLSBAD, Calif., Oct. 22, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that the first patients have been dosed with I...

PRNewsWire - 1 month ago

CARLSBAD, Calif., Oct. 21, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 4th at 11:30 a.m. Eastern Tim...

Seeking Alpha - 1 month ago

Ionis With Akcea: Still A Bargain

Other stocks mentioned: AKCA
Forbes - 1 month ago

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma co...

Other stocks mentioned: ALKS, NBIX, ACAD, ARWR, BMRN
The Motley Fool - 1 month ago

Here's what it takes to justify the current valuation.

PRNewsWire - 1 month ago

CARLSBAD, Calif., Oct. 15, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that IONIS-PKK-LRx is being evaluated in an in...

PRNewsWire - 1 month ago

CARLSBAD, Calif., Oct. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that data from a clinical trial of IONIS-ENAC-...

Zacks Investment Research - 2 months ago

The FDA assigns an orphan drug designation to Ionis' (IONS) pipeline candidate ION373 for treating patients with Alexander disease.

PRNewsWire - 2 months ago

BOSTON and CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ: IONS), the leader in antisense therapeut...

PRNewsWire - 2 months ago

CARLSBAD, Calif., Sept. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration (F...

Zacks Investment Research - 3 months ago

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 3 months ago

CARLSBAD, Calif., Sept. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Zacks Investment Research - 3 months ago

Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.

Other stocks mentioned: AKCA
The Motley Fool - 3 months ago

The biotech is being acquired by its largest shareholder.

Other stocks mentioned: AKCA
Newsfile Corp - 3 months ago

(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders ewsfilecorp.com...

Other stocks mentioned: AKCA
24/7 Wall Street - 3 months ago

Akcea Therapeutics Inc. (NASDAQ: AKCA) stock jumped on Monday after it was announced that Ionis Pharmaceuticals Inc.

Other stocks mentioned: AKCA
Benzinga - 3 months ago

Akcea Therapeutics Inc (NASDAQ: AKCA) shares were rallying strongly Monday following a buyout deal.

Other stocks mentioned: AKCA
PRNewsWire - 3 months ago

BOSTON and CARLSBAD, Calif., Aug. 29, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc.

PRNewsWire - 3 months ago

BOSTON and CARLSBAD, Calif., Aug. 29, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc.

PRNewsWire - 3 months ago

CARLSBAD, Calif., Aug. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

PRNewsWire - 3 months ago

BOSTON and CARLSBAD, Calif., Aug. 24, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc.

PRNewsWire - 3 months ago

BOSTON and CARLSBAD, Calif., Aug. 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc.

Zacks Investment Research - 3 months ago

Ionis (IONS) posts narrower-than-expected Q2 loss. Sales miss estimates.

Seeking Alpha - 3 months ago

Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 17.86% and -3.17%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the ...

Benzinga - 3 months ago

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) remained unaffected after the company reported Q2 results.

Zacks Investment Research - 4 months ago

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 4 months ago

CARLSBAD, Calif., July 22, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

About IONS

Ionis Pharmaceuticals discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (A... [Read more...]

Industry
Biotechnology
IPO Date
May 17, 1991
CEO
Brett Monia
Employees
817
Stock Exchange
NASDAQ
Ticker Symbol
IONS
Full Company Profile

Financial Performance

In 2019, IONS's revenue was $1.12 billion, an increase of 87.20% compared to the previous year's $599.67 million. Earnings were $294.15 million, an increase of 7.45%.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for IONS is 67.11, which is an increase of 31.02% from the latest price.

Price Target
$67.11
(31.02% upside)